Augmentation of Vascular Remodeling by Uncoupled Endothelial Nitric Oxide Synthase in a Mouse Model of Diabetes Mellitus

  • Naoto Sasaki
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.
  • Tomoya Yamashita
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.
  • Tomofumi Takaya
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.
  • Masakazu Shinohara
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.
  • Rio Shiraki
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.
  • Masafumi Takeda
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.
  • Noriaki Emoto
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.
  • Akiko Fukatsu
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.
  • Toshio Hayashi
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.
  • Kazuhisa Ikemoto
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.
  • Takahide Nomura
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.
  • Mitsuhiro Yokoyama
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.
  • Ken-ichi Hirata
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.
  • Seinosuke Kawashima
    From the Division of Cardiovascular Medicine, Department of Internal Medicine (N.S., T.Y., T.T., M.S., R.S., M.T., N.E., M.Y., K.H., S.K.), Kobe University Graduate School of Medicine, Kobe, Japan; the Department of Geriatrics (A.F., T.H.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Pharmacology (K.I., T.N.), School of Medicine, Fujita Health University, Aichi, Japan; and the Department of General Medicine (S.K.), Nakatsu Saiseikai Hospital, Osaka, Japan.

抄録

<jats:p> <jats:bold> <jats:italic>Objective—</jats:italic> </jats:bold> Diabetes mellitus is associated with increased oxidative stress, which induces oxidation of tetrahydrobiopterin (BH4) in vessel wall. Without enough BH4, eNOS is uncoupled to L-arginine and produces superoxide rather than NO. We examined the role of uncoupled eNOS in vascular remodeling in diabetes. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> Diabetes mellitus was produced by streptozotocin in C57BL/6J mice. Under stable hyperglycemia, the common carotid artery was ligated, and neointimal formation was examined 4 weeks later. In diabetic mice, the neointimal area was dramatically augmented. This augmentation was associated with increased aortic superoxide formation, reduced aortic BH4/dihydrobiopterin (BH2) ratio, and decreased plasma nitrite and nitrate (NOx) levels compared with nondiabetic mice. Chronic BH4 treatment (10 mg/kg/d) reduced the neointimal area in association with suppressed superoxide production and inflammatory changes in vessels. BH4/BH2 ratio in vessel wall was preserved, and plasma NOx levels increased. Furthermore, in the presence of diabetes, overexpression of bovine eNOS resulted in augmentation of neointimal area, accompanied by increased superoxide production in the endothelium. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> In diabetes, increased oxidative stress by uncoupled NOSs, particularly eNOS, causes augmentation of vascular remodeling. These findings indicate restoration of eNOS coupling has an atheroprotective benefit in diabetes. </jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ